Resveratrol: why is it a promising therapy for chronic kidney disease patients?
Resveratrol, a phenolic compound found in various plants, including grapes, berries, and peanuts, shows promise for the treatment of cancer, aging, type 2 diabetes, and cardiovascular diseases. Resveratrol can promote transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2) activation, increase the expression level of SIRT-1, which is a sirtuin family protein, and reduce mTOR pathway signaling. This compound has anti-inflammatory properties in that it inhibits or antagonizes the nuclear factor-κB (NF-κB) activity, which is a redox-sensitive transcription factor that coordinates the inflammatory response. Inflammation and oxidative stress, which are common features in patients with chronic kidney disease (CKD), are interrelated and associated with cardiovascular disease and the progression of CKD itself. Because of the modulation of the mechanisms involved in the inflammatory-oxidative stress cycle, resveratrol could play an important role in controlling CKD-related metabolic derangements. Although resveratrol supplementation in theory is a promising therapy in this patient group, there are no studies evaluating its effects. Thus, the present review aims to describe the role of resveratrol in inflammation and oxidative stress modulation and its possible benefits to patients with CKD.
Graduate Program in Medical Sciences, Federal Fluminense University (UFF), Niteroi, RJ, Brazil.
Juliana F
JF
Saldanha
Clinical Nutrition Department, State University of Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil.
Viviane de O
Vde O
Leal
Department of Renal Medicine K56, Huddinge University Hospital, Karolinska Institutet, 141 86 Stockholm, Sweden.
Peter
P
Stenvinkel
University Hospital Antonio Pedro, Medicine Faculty of Federal Fluminense University (UFF), Niteroi, RJ, Brazil.
José Carlos
JC
Carraro-Eduardo
Graduate Program in Medical Sciences, Federal Fluminense University (UFF), Niteroi, RJ, Brazil.
Denise
D
Mafra
D006801:Humans; D007249:Inflammation / Q000473:pathology; D000076222:Mechanistic Target of Rapamycin Complex 1; D000076225:Mechanistic Target of Rapamycin Complex 2; D046912:Multiprotein Complexes / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy*; D000077185:Resveratrol; D013267:Stilbenes / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism
D046912:Multiprotein Complexes; D013267:Stilbenes; D000076222:Mechanistic Target of Rapamycin Complex 1; D000076225:Mechanistic Target of Rapamycin Complex 2; D058570:TOR Serine-Threonine Kinases; D000077185:Resveratrol